![]() |
市場調查報告書
商品編碼
1738751
2026 年至 2032 年無創血糖監測設備市場(按產品類型、通路、最終用戶和地區)Non-Invasive Blood Glucose Monitoring Devices Market By Product Type (Self-Monitoring Blood Glucose Devices, Glucose Sstrips), Distribution Channel (Retail, Specialty Stores), End- User (Hospital and Home Healthcare) & Region for 2026-2032 |
非侵入性血糖監測設備需求持續成長 近年來,隨著糖尿病盛行率的不斷上升,消費者也越來越意識到血糖監測設備的益處。疫情期間,虛擬診所和遠端醫療在治療多種疾病(包括糖尿病)的應用顯著增加。由於重症糖尿病及其他合併症住院患者數量眾多,醫院細分市場在全球血糖監測設備市場中佔據終端用戶細分市場的最高佔有率。預計2024年市場規模將超過3,701萬美元,2032年將達3.2493億美元。
非侵入性血糖監測設備使患者能夠持續、無痛地監測血糖濃度。對具有先進功能的智慧糖尿病管理設備的需求預計將推動市場成長。對經濟高效的非侵入性血糖監測設備的需求不斷成長,推動市場在2026年至2032年間以31.20%的複合年成長率成長。
非侵入性血糖監測設備市場定義/概述
血糖監測是使用血糖儀測量血液中的血糖濃度(血糖值)。血糖值檢測在糖尿病治療中尤其重要,通常透過刺穿皮膚(通常用指尖刺破)來獲取血液樣本,並將其滴到具有化學活性的拋棄式上進行。
血糖監測設備是檢測血糖值的重要工具,種類繁多,包括血糖儀、試紙和採血針。這些設備可方便患者在家中輕鬆測量血糖值,並對治療方案進行必要的調整。這採血針患者及其醫生能夠識別血糖值高低,並對治療方案進行必要的調整。血糖監測設備徹底改變了糖尿病治療,使患者能夠更好地掌控自身健康,並降低急性低血糖和高血糖的風險。
非侵入性血糖監測設備可測量糖尿病患者的血糖值。非侵入性血糖監測無需刺穿皮膚,也不會帶給使用者疼痛或創傷。非侵入性檢測血糖濃度有助於改善糖尿病患者的血糖控制和生活品質。此外,它還可用於治療第1型和第2型糖尿病患者。
非侵入性血糖監測市場日益普及:糖尿病在全球日益普遍,直接影響著非侵入性血糖監測設備市場的成長。如果高血糖得不到有效控制,可能會對器官和組織造成長期損害。血糖值監測對於糖尿病管理至關重要,因為它可以讓患者和醫護人員準確地了解過去2-3個月的整體血糖控制。
糖尿病盛行率的上升可能會在預測期內推動全球非侵入式血糖監測設備市場的成長。美國糖尿病協會 (ADA) 建議,對於達到治療目標且血糖控制穩定的患者,應至少每年測量兩次糖化血紅蛋白 (HbA1c) 水平;對於藥物已更改或血糖未達到目標的患者,應每季度測量一次。
根據國際糖尿病聯盟的數據,2021年約有5.2億20至79歲的人患有糖尿病,預計到2045年這一數字將上升到7億。全球超過90%的糖尿病患者患有第2型糖尿病。
最重要的因素是非侵入性血糖監測儀 (NIBGM) 的日益普及。準確性和可靠性對於糖尿病患者的治療至關重要。目前,NIBGM 設備可能並不總是像傳統方法那樣準確,這引起了依賴高精度數據的用戶的擔憂。
糖尿病患者已經形成了既定的治療習慣,並習慣使用一些老方法。切換到一項新技術,尤其是準確性可能存疑的技術,可能會令人感到擔憂。除非我們對NIBGM的準確性和易用性有信心,否則我們會謹慎地引入它。
非侵入性血糖監測設備通常比標準監測設備更昂貴。這可能是一個重大障礙,尤其是對於經濟資源有限或保險覆蓋較差的患者。初始投資成本可能會使 NIBGM 對某些人缺乏吸引力。
Rising demand for non-invasive blood glucose monitoring devices consumers have been more aware of the benefits of blood glucose monitoring devices in recent years as the prevalence of diabetes has increased. During the pandemic, there was a significant increase in the use of virtual clinics and telemedicine to treat multiple illnesses including diabetes care. The hospital segment accounted for the highest proportion of the worldwide glucose monitoring devices market's end-user segment, as many patients are admitted due to severe diabetes and other concurrent conditions. The market size surpass USD 37.01 Million valued in 2024 to reach a valuation of around USD 324.93 Million by 2032.
Non-invasive blood glucose monitoring devices provide continuous, painless surveillance of a patient's glucose levels. Demand for smart diabetes management devices with advanced features is expected to boost the market. The rising demand for cost-effective and efficient non-invasive blood glucose monitoring devices is enabling the market grow at a CAGR of 31.20% from 2026 to 2032.
Non-Invasive Blood Glucose Monitoring Devices Market: Definition/ Overview
Blood glucose monitoring is the use of a glucose monitor to determine the level of glucose in the blood (glycemia). A blood glucose test, which is especially crucial in diabetes treatment, is commonly performed by piercing the skin (usually with a fingerstick) and drawing blood, which is then applied to a chemically active disposable.
Glucose monitoring devices are an essential tool for detecting the sugar level in the blood, and they come in various types, including glucose meters, testing strips, and lancets. With the help of these devices, people can easily test their blood glucose levels at home and make necessary adjustments to their therapy. This allows individuals and their doctors to identify high or low blood glucose levels and make necessary changes to their treatment plan. Glucose monitoring devices have revolutionized diabetes care by offering patients greater control over their health and reducing the risk of acute hypoglycemia or hyperglycemia.
Non-invasive blood glucose monitoring devices measure blood glucose levels in diabetic individuals. Non-invasive glucose monitoring involves measuring blood without piercing the skin or causing pain or trauma to the consumer, which is why non-invasive gadgets are so popular. Non-invasive detection of blood glucose concentration improves blood sugar control and the quality of life for diabetics. Furthermore, it is utilized to treat both Type 1 and Type 2 diabetic patients.
Rising Prevalence in non-invasive blood glucose monitoring market, Diabetes has grown more common around the world, which has a direct impact on the growth of the non-invasive blood glucose monitoring equipment market. If high blood sugar is not effectively controlled it can cause long-term harm to organs and tissues. Monitoring blood sugar levels has become critical for diabetes management since it gives patients and healthcare professionals an accurate view of overall blood sugar control over the previous 2-3 months.
The rising prevalence of diabetes is likely to drive the growth of the global non-invasive blood glucose monitoring devices market over the predicted period. The American Diabetes Association (ADA) recommends measuring HbA1c levels at least twice a year for patients who are meeting treatment objectives and have stable glycemic control, and quarterly for patients whose medication has changed or who are not meeting glycemic goals.
According to the International Diabetes Federation, roughly 520 million persons aged 20 to 79 had diabetes in 2021, and this figure is anticipated to climb to 700 million by 2045. Type 2 diabetes accounts for more than 90% of diabetes cases worldwide.
The most significant factor is are expanding prevalence of non-invasive blood glucose monitor (NIBGM), it is a very new technology as compared to older finger-prick procedures. Accuracy and dependability are critical for diabetics in treating their condition. Currently, NIBGM devices may not always equal the precision of older methods, raising concerns among users who rely on extremely accurate data.
People with diabetes have established routines and are familiar with older procedures. Switching to a new technology, particularly one with potential accuracy issues can be scary. They may be cautious to adopt NIBGM unless they have trust in its accuracy and usability.
Non-Invasive blood glucose monitoring devices are typically more expensive than standard monitors. This can be a substantial hurdle for patients especially those with little financial resources or insufficient insurance coverage. The initial investment expense may make NIBGM less appealing for some.
The self-monitoring devices segment is substantially leading the non-invasive blood glucose monitoring devices market owing to the catering to individuals with diabetes who require regular monitoring of their blood sugar levels. This market includes a variety of self-testing products, such as glucose strips, glucose meters, and lancets. These devices enable diabetics to easily and accurately monitor their glucose levels at home, allowing them to make educated decisions regarding their diabetes treatment routine.
Glucose meters are booming the non-invasive blood glucose monitoring devices market, glucose meters are handheld electronic devices used to measure and display blood glucose levels based on the readings obtained from glucose strips. These meters play a critical role in self-monitoring blood glucose devices, providing users with real-time feedback on their glucose levels. The glucose meter segment is characterized by ongoing technological advancements aimed at improving accuracy, speed, and user-friendliness. Key features such as wireless connectivity, data storage, and compatibility with mobile apps are increasingly incorporated into glucose meters to enhance usability and convenience for individuals managing diabetes.
The home healthcare segment dominates the market for non-invasive blood glucose monitoring devices, the hospital segment is seeing significant growth opportunities due to increased adoption of advanced monitoring technologies and a growing emphasis on improving diabetes management in healthcare facilities.
Due to a number of factors, including an increase in the global prevalence of diabetes, a greater emphasis on patient-centered care, and a growing desire for convenient and accessible monitoring systems. Individuals with diabetes prefer the convenience and privacy of monitoring their blood glucose levels at home rather than frequent visits to healthcare institutions. Non-invasive blood glucose monitoring devices designed for home usage provide ease of use, portability, and real-time data tracking, empowering patients to efficiently manage their condition between healthcare consultations.
While the home healthcare segment leads the industry, the hospital segment is rapidly expanding and deemed thriving. Hospitals continue to be significant end users of non-invasive blood glucose monitoring devices, particularly for diabetes management in hospitalized patients and those requiring intensive care.
North America emerges as the leading force in the projected market for non-invasive blood glucose monitoring devices, in 2019, North America led the global market for non-invasive blood glucose monitoring devices by revenue, followed by Europe. The region's huge market share can be due to its high disease prevalence and well-established healthcare infrastructure, which allows for accurate diagnosis. In 2018, the American Diabetes Association reported that 34.2 million people in the United States had diabetes, accounting for 10.5% of the population. Type 1 diabetes affects 1.6 million people, including around 187,000 children and adolescents.
North America's dominance in the predicted market for non-invasive blood glucose monitoring devices is due to excellent reimbursement policies, greater diabetes awareness, well-developed healthcare infrastructure, and a supportive regulatory environment. As these factors continue to drive demand and acceptance, North America is expected to maintain its dominance in the global market for non-invasive blood glucose monitoring devices.
The Asia Pacific market is poised to grow rapidly during the projected period, driven primarily by the rising prevalence of diabetes and increased knowledge about its diagnosis and treatment. This increase in diabetes prevalence is especially noticeable in Asia Pacific, where the majority of countries are experiencing rapid economic growth. As a result, many healthcare companies are making significant investments in the region to capitalize on the growing demand for non-invasive blood glucose monitoring devices and related technology. These collaborative efforts are critical in driving the market's growth throughout Asia Pacific.
According to data from the International Diabetes Federation (IDF), the prevalence of diabetes is increasing in developing nations, owing to rapid and ongoing socioeconomic changes. This trend is projected to continue, driving up demand for non-invasive blood glucose monitoring devices in Asia Pacific.
As the region's economies mature and healthcare infrastructure improves, there is an increasing need to treat the rising diabetes burden. As a result, the combination of rising illness prevalence, increased awareness, and significant investments highlights the non-invasive blood glucose monitoring devices market's enormous growth potential in Asia Pacific.
The non-invasive blood glucose monitoring devices market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.
The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the non-invasive blood glucose monitoring devices market include: